{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:45:43Z","timestamp":1793213143786,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.yrtph.2024.105762","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T17:04:59Z","timestamp":1733763899000},"page":"105762","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Control of N-nitrosamine impurities in drug products: Progressing the current CPCA framework and supporting the derivation of robust compound specific acceptable intakes"],"prefix":"10.1016","volume":"156","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6840-2629","authenticated-orcid":false,"given":"David J.","family":"Ponting","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5106-3325","authenticated-orcid":false,"given":"Andreas","family":"Czich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6431-2028","authenticated-orcid":false,"given":"Susan P.","family":"Felter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3594-1443","authenticated-orcid":false,"given":"Susanne","family":"Glowienke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6656-375X","authenticated-orcid":false,"given":"James S.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6005-7725","authenticated-orcid":false,"given":"Raphael","family":"Nudelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4799-1086","authenticated-orcid":false,"given":"Joerg","family":"Schlingemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2497-5211","authenticated-orcid":false,"given":"Stephanie","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0393-3650","authenticated-orcid":false,"given":"Graham F.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0309-8712","authenticated-orcid":false,"given":"Andrew","family":"Teasdale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0261-8720","authenticated-orcid":false,"given":"Robert","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"April","key":"10.1016\/j.yrtph.2024.105762_bib1","article-title":"Use of less-than-lifetime (LTL) durational limits for nitrosamines : case study of N -nitrosodiethylamine (NDEA)","volume":"123","author":"Bercu","year":"2021","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2024.105762_bib2","article-title":"A nitrite excipient database : a useful tool to support N- nitrosamine risk assessments for drug products","author":"Boetzel","year":"2022","journal-title":"J. Pharm. Sci."},{"issue":"12","key":"10.1016\/j.yrtph.2024.105762_bib3","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1016\/j.xphs.2023.10.001","article-title":"Revisiting the landscape of potential small and drug substance related nitrosamines in pharmaceuticals","volume":"112","author":"Burns","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.yrtph.2024.105762_bib4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/em.22618","article-title":"Evaluation of the nitrosamine impurities of ACE inhibitors using computational, in vitro, and in vivo methods demonstrate No genotoxic potential","volume":"67","author":"Cheung","year":"2024","journal-title":"Environ. Mol. Mutagen."},{"key":"10.1016\/j.yrtph.2024.105762_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.comtox.2021.100186","article-title":"Developing structure-activity relationships for N-nitrosamine activity","volume":"20","author":"Cross","year":"2021","journal-title":"Comput. Toxicol."},{"key":"10.1016\/j.yrtph.2024.105762_bib6","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1021\/acs.chemrestox.1c00369","article-title":"Practical and science-based strategy for establishing acceptable intakes for drug product N - nitrosamine impurities","volume":"35","author":"Dobo","year":"2022","journal-title":"Chem. Res. Toxicol."},{"issue":"2","key":"10.1016\/j.yrtph.2024.105762_bib7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00524152","article-title":"Organotrope carcinogene wirkungen bei 65 verschiedenen N-Nitroso-Verbindungen an BD-ratten","volume":"69","author":"Druckrey","year":"1967","journal-title":"Z. Krebsforsch."},{"issue":"3","key":"10.1016\/j.yrtph.2024.105762_bib8","article-title":"Review of the threshold of toxicological concern (TTC) approach and development of new TTC decision tree","volume":"13","year":"2016","journal-title":"EFSA Support. Publ."},{"key":"10.1016\/j.yrtph.2024.105762_bib9","series-title":"Procedure under Article 5(3) of Regulation EC (No) 726\/2004: Nitrosamine Impurities in Human Medicinal Products","year":"2020"},{"key":"10.1016\/j.yrtph.2024.105762_bib10","year":"2024","journal-title":"Questions and Answers for Marketing Authorisation Holders\/Applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726\/2004 Referral on Nitrosamine Impurities in Human Medicinal Products. EMA\/409815\/2020 Rev. 21 and Appendices"},{"key":"10.1016\/j.yrtph.2024.105762_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2023.105459","article-title":"Maximizing use of existing carcinogenicity data to support acceptable intake levels for mutagenic impurities in pharmaceuticals: learnings from N-nitrosamine case studies","volume":"143","author":"Felter","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2024.105762_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2023.105505","article-title":"Nitrosamine acceptable intakes should consider variation in molecular weight: the implication of stoichiometric DNA damage","volume":"145","author":"Fine","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"11","key":"10.1016\/j.yrtph.2024.105762_bib13","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1021\/acs.oprd.3c00274","article-title":"N-nitrosodimethylamine formation in metformin drug products by the reaction of dimethylamine and atmospheric NO2","volume":"27","author":"Fukuda","year":"2023","journal-title":"Org. Process Res. Dev."},{"issue":"1","key":"10.1016\/j.yrtph.2024.105762_bib14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0015-6264(80)90015-2","article-title":"Lack of carcinogenic effect of nitrosochlordiazepoxide and of nitrosomethylphenidate given orally to mice","volume":"18","author":"Giner-Sorolla","year":"1980","journal-title":"Food Cosmet. Toxicol."},{"key":"10.1016\/j.yrtph.2024.105762_bib15","series-title":"Comprehensive Organic Synthesis","first-page":"705","article-title":"Wagner\u2013meerwein rearrangements","author":"Hanson","year":"1991"},{"key":"10.1016\/j.yrtph.2024.105762_bib17","series-title":"Guidance on Nitrosamine Impurities in Medications. Revision as of 31st May 2024","year":"2024"},{"issue":"11","key":"10.1016\/j.yrtph.2024.105762_bib18","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.3390\/pr10112428","article-title":"Assessment of a diverse array of nitrite scavengers in solution and solid state: a study of inhibitory effect on the formation of alkyl-aryl and dialkyl N-nitrosamine derivatives","volume":"10","author":"Hom\u0161ak","year":"2022","journal-title":"Processes"},{"key":"10.1016\/j.yrtph.2024.105762_bib19","series-title":"Q3B (R2): Impurities in New Drug Products","year":"2006"},{"key":"10.1016\/j.yrtph.2024.105762_bib20","series-title":"M7(R2): Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk","year":"2023"},{"key":"10.1016\/j.yrtph.2024.105762_bib21","article-title":"ICH","year":"2006","journal-title":"Q3A(R2): Impurities in New Drug Substances"},{"issue":"2\u20133","key":"10.1016\/j.yrtph.2024.105762_bib22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0278-6915(99)00120-9","article-title":"Threshold of toxicological concern for chemical substances present in the diet: a practical tool for assessing the need for toxicity testing","volume":"38","author":"Kroes","year":"2000","journal-title":"Food Chem. Toxicol."},{"issue":"1","key":"10.1016\/j.yrtph.2024.105762_bib23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.fct.2003.08.006","article-title":"Structure-based thresholds of toxicological concern (TTC): guidance for application to substances present at low levels in the diet","volume":"42","author":"Kroes","year":"2004","journal-title":"Food Chem. Toxicol."},{"issue":"2","key":"10.1016\/j.yrtph.2024.105762_bib24","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/toxsci\/kfi169","article-title":"The threshold of toxicological concern concept in risk assessment","volume":"86","author":"Kroes","year":"2005","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.yrtph.2024.105762_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2024.105640","article-title":"Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: development and application of the carcinogenic potency categorization approach (CPCA)","author":"Kruhlak","year":"2024","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"7","key":"10.1016\/j.yrtph.2024.105762_bib26","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1021\/acs.jmedchem.5b01963","article-title":"Structure property relationships of carboxylic acid isosteres","volume":"59","author":"Lassalas","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.yrtph.2024.105762_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2023.105410","article-title":"Revisiting the mutagenicity and genotoxicity of N-nitroso propranolol in bacterial and human in vitro assays","volume":"141","author":"Li","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"8","key":"10.1016\/j.yrtph.2024.105762_bib28","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1021\/jm1013693","article-title":"Synopsis of some recent tactical application of bioisosteres in drug design","volume":"54","author":"Meanwell","year":"2011","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.yrtph.2024.105762_bib29","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0278-6915(96)00049-X","article-title":"Correlation of structural class with No-Observed-Effect levels: a proposal for establishing a threshold of concern","volume":"34","author":"Munro","year":"1996","journal-title":"Food Chem. Toxicol."},{"issue":"10","key":"10.1016\/j.yrtph.2024.105762_bib30","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1021\/acs.oprd.3c00100","article-title":"The nitrosamine \u201csaga\u201d: lessons learned from five years of scrutiny","volume":"27","author":"Nudelman","year":"2023","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.yrtph.2024.105762_bib31","first-page":"6415","article-title":"Effects on 4080 rats of chronic ingestion of N-nitrosodiethylamine or N-nitrosodimethylamine: a detailed dose-response study","volume":"51","author":"Peto","year":"1991","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.yrtph.2024.105762_bib32","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1021\/acs.oprd.3c00008","article-title":"Drawing a line: where might the cohort of concern end?","volume":"27","author":"Ponting","year":"2023","journal-title":"Org. Process Res. Dev."},{"issue":"23","key":"10.1016\/j.yrtph.2024.105762_bib33","doi-asserted-by":"crossref","first-page":"15584","DOI":"10.1021\/acs.jmedchem.2c01498","article-title":"Strategies for assessing acceptable intakes for novel N-nitrosamines derived from active pharmaceutical ingredients","volume":"65","author":"Ponting","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.yrtph.2024.105762_bib34","first-page":"435","article-title":"Use of Lhasa limited products for the in silico prediction of drug toxicity","volume":"vol. 2425","author":"Ponting","year":"2022"},{"issue":"30","key":"10.1016\/j.yrtph.2024.105762_bib35","doi-asserted-by":"crossref","first-page":"20615","DOI":"10.1039\/C6CP02936A","article-title":"Quantification and classification of substituent effects in organic chemistry: a theoretical molecular electrostatic potential study","volume":"18","author":"Remya","year":"2016","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.yrtph.2024.105762_bib36","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.xphs.2022.11.013","article-title":"The landscape of potential small and drug substance related nitrosamines in pharmaceuticals","volume":"112","author":"Schlingemann","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.yrtph.2024.105762_bib37","series-title":"Committee on Risk Assessment of Hazardous Air Pollutants","year":"1994"},{"issue":"3\u20134","key":"10.1016\/j.yrtph.2024.105762_bib38","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/biomet\/52.3-4.591","article-title":"An analysis of variance test for normality (complete samples)","volume":"52","author":"Shapiro","year":"1965","journal-title":"Biometrika"},{"key":"10.1016\/j.yrtph.2024.105762_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2023.105403","article-title":"Mutagenic impurities in pharmaceuticals: a critical assessment of the cohort of concern with a focus on N-nitrosamines","volume":"141","author":"Snodin","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2024.105762_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2021.104875","article-title":"Utilisation of parametric methods to improve percentile-based estimates for the carcinogenic potency of nitrosamines","volume":"121","author":"Thomas","year":"2021","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2024.105762_bib41","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1021\/acs.chemrestox.2c00199","article-title":"What makes a potent nitrosamine? Statistical validation of expert-derived structure activity relationships","volume":"11","author":"Thomas","year":"2022","journal-title":"Chem. Res. Toxicol."},{"issue":"June","key":"10.1016\/j.yrtph.2024.105762_bib42","article-title":"Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data","volume":"116","author":"Thresher","year":"2020","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2024.105762_bib43","year":"2021","journal-title":"Control of Nitrosamine Impurities in Human Drugs, Guidance for Industry"},{"key":"10.1016\/j.yrtph.2024.105762_bib44","series-title":"Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities (NDSRIs). Revision as of 4th September 2024","year":"2024"},{"issue":"6","key":"10.1016\/j.yrtph.2024.105762_bib45","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/j.bmcl.2008.01.127","article-title":"Carboxylic acid bioisosteres acylsulfonamides, acylsulfamides, and sulfonylureas as novel antagonists of the CXCR2 receptor","volume":"18","author":"Winters","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230024002034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230024002034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T11:29:43Z","timestamp":1739273383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230024002034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":44,"alternative-id":["S0273230024002034"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2024.105762","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Control of N-nitrosamine impurities in drug products: Progressing the current CPCA framework and supporting the derivation of robust compound specific acceptable intakes","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2024.105762","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"105762"}}